A three-compound dengue treatment; plus reversing antibiotic resistance, AbCellera-Lilly, reducing cholesterol with CRISPR and COVID cash for Sherlock

BioCentury’s roundup of preclinical news

Hindering dengue by combining host- and virus-targeted drugs
In a Cell Chemical Biology article, Stanford University scientists combined two host-targeted compounds with a virus-targeted compound to yield potent dengue treatment. A DHODH inhibitor tool compound, which blocks de novo pyrimidine synthesis, plus a cyclopentenyl uracil analog that inhibits pyrimidine salvage suppressed

Read the full 507 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE